0000899243-23-016481.txt : 20230626 0000899243-23-016481.hdr.sgml : 20230626 20230626160521 ACCESSION NUMBER: 0000899243-23-016481 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230626 FILED AS OF DATE: 20230626 DATE AS OF CHANGE: 20230626 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Parkinson David Ross CENTRAL INDEX KEY: 0001451935 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28386 FILM NUMBER: 231042366 MAIL ADDRESS: STREET 1: C/O THRESHOLD PHARMACEUTICALS, INC. STREET 2: 170 HARBOR WAY SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-26 1 0000891293 CTI BIOPHARMA CORP CTIC 0001451935 Parkinson David Ross 3101 WESTERN AVENUE, SUITE 800 SEATTLE WA 98121 1 0 0 0 0 Stock Option (Right to Buy) 4.07 2023-06-26 4 D 0 50000 D Common Stock 50000 0 D Stock Option (Right to Buy) 4.61 2023-06-26 4 D 0 60000 D Common Stock 60000 0 D Stock Option (Right to Buy) 0.8411 2023-06-26 4 D 0 120000 D Common Stock 120000 0 D Stock Option (Right to Buy) 1.00 2023-06-26 4 D 0 126000 D Common Stock 126000 0 D Stock Option (Right to Buy) 3.30 2023-06-26 4 D 0 80000 D Common Stock 80000 0 D Stock Option (Right to Buy) 4.49 2023-06-26 4 D 0 80000 D Common Stock 80000 0 D Stock Option (Right to Buy) 4.08 2023-06-26 4 D 0 80000 D Common Stock 80000 0 D Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. /s/ Adam R. Craig, attorney-in-fact for David Ross Parkinson 2023-06-26